Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.68 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KLK3 | P07288 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2079102 | 0.98 | NNMT (0.66) | NNMTMKNK1MKNK2ABCB1SIRT6 | |
| SCHEMBL13116536 | 0.81 | MAPT (0.62) | NNMTMKNK1MKNK2ABCB1MAPT | |
| SCHEMBL71905 | 0.81 | NNMT (1.00) | NNMTMKNK1MKNK2SIRT6MEN1 | |
| SCHEMBL29975550 | 0.81 | NNMT (1.00) | NNMTMKNK1MKNK2SIRT6MEN1 | |
| SCHEMBL1924984 | 0.81 | NNMT (0.68) | NNMTMKNK1MKNK2SIRT6 | |
| SCHEMBL3816353 | 0.80 | NNMT (0.45) | NNMTMKNK1MKNK2ABCB1RAB9A | |
| Hydrochloric Acid SCHEMBL23906967 | 0.79 | NNMT (0.66) | NNMTMKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL31152512 | 0.79 | NNMT (0.66) | NNMTMKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL6234386 | 0.79 | NNMT (0.96) | NNMTMKNK1MKNK2SIRT6MAOA | |
| Hydrochloric Acid SCHEMBL5013391 | 0.79 | NNMT (0.96) | NNMTMKNK1MKNK2SIRT6MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020125615-A1 | C-TERMINAL SRC KINASE INHIBITORS | INVENTISBIO SHANGHAI LTD. (CN) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020124397-A1 | C-TERMINAL SRC KINASE INHIBITORS | INVENTISBIO SHANGHAI LTD. (CN) | 2020-06-25 | — | — | WO | disclosed |
| US-20130102605-A1 | INHIBITORS OF AKT ACTIVITY | LIANG PENG (CN) | 2013-04-25 | — | — | US | disclosed |
| EP-2231652-B1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Bayer Pharma AG (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-8148411-B2 | 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-03 | — | — | US | disclosed |
| US-8148411-B2 | 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-03 | — | — | US | disclosed |
| US-8148411-B2 | 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2012-02-02 | — | — | US | disclosed |
| WO-2011130921-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-8039487-B2 | Piperidine-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER SCHERING PHARMA AG (DE) | 2009-08-13 | — | — | US | disclosed |
| WO-2009074246-A1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| EP-2070924-A1 | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2070924-A1 | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008145596-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-04 | — | — | US | disclosed |
| US-20070032518-A1 | Compounds and methods of use | AMGEN INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1478645-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | Amgen Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-6822097-B1 | THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS | AMGEN, INC. | 2004-11-23 | — | — | US | disclosed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | PIK3CA, G6PC1, PIK3C2B | NNMT 3208/4885MKNK1 2412/4885MKNK2 2007/4885 |
| US-20070032518-A1 | Compounds and methods of use | BAX, BAD, CASP3 | NNMT 105/4885MKNK1 1842/4885MKNK2 2228/4885 |
| US-20130102605-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, PIK3CD, AKT2 | NNMT 1643/4885MKNK1 103/4885MKNK2 101/4885 |
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | CPT1A, CPT1B, CPT2 | NNMT 1244/4885MKNK1 4511/4885MKNK2 4423/4885 |
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | CNR2, CYP11B2, CYP2C19 | NNMT 659/4885MKNK1 3954/4885MKNK2 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.